Literature DB >> 16936339

Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan.

Chien-Ching Hung1, Chin-Fu Hsiao, Mao-Yuan Chen, Szu-Min Hsieh, Sui-Yuan Chang, Wang-Huei Sheng, Hsin-Yun Sun, Shan-Chwen Chang.   

Abstract

We assessed the survival of 1,044 HIV-infected persons enrolled in three periods: period 1, 1994 to 1997 (before the introduction of highly active antiretroviral therapy [HAART]); period 2, 1997 to 2000 (early-HAART); and period 3, 2000 to 2004 (late-HAART). As of 30 June 2005, 259 (24.8%) persons had died after a median observation duration of 985 days (range, 2 - 4,025 days). The mortality rate declined from 33.75 per 100 person-years in the pre-HAART era to 6.51 per 100 person-years in the late-HAART era (P < 0.0001). The adjusted hazard ratios for death in persons with a baseline CD4 count of <200 cells/mul in periods 2 and 3 were 0.605 (P = 0.007) and 0.371 (P < 0.0001), respectively, when compared with persons enrolled in period 1; the adjusted hazard ratio for death was 0.611 for persons enrolled in period 3 when compared to period 2 (P = 0.01). Our study suggested that the survival of persons in the late stage of HIV infection in Taiwan continued to improve in the late HAART era.

Entities:  

Mesh:

Year:  2006        PMID: 16936339

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  5 in total

1.  Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy.

Authors:  Chien-Yu Cheng; Mao-Yuan Chen; Szu-Min Hsieh; Wang-Huei Sheng; Hsin-Yun Sun; Yi-Chun Lo; Wen-Chun Liu; Chien-Ching Hung
Journal:  BMC Infect Dis       Date:  2010-05-21       Impact factor: 3.090

2.  Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: etiology and prognostic factors.

Authors:  Hou-Hsien Chiang; Chien-Ching Hung; Chang-Min Lee; Hsuan-Yu Chen; Mao-Yuan Chen; Wang-Huei Sheng; Szu-Min Hsieh; Hsin-Yun Sun; Chao-Chi Ho; Chong-Jen Yu
Journal:  Crit Care       Date:  2011-08-26       Impact factor: 9.097

3.  Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants.

Authors:  Hiroshi Ohrui
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2011       Impact factor: 3.493

4.  Risk of Active Tuberculosis in HIV-Infected Patients in Taiwan with Free Access to HIV Care and a Positive T-Spot.TB Test.

Authors:  Hsin-Yun Sun; Po-Ren Hsueh; Wen-Chun Liu; Yi-Ching Su; Sui-Yuan Chang; Chien-Ching Hung; Shan-Chwen Chang
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

5.  Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy.

Authors:  Shannon L Turvey; Sean M Bagshaw; Dean T Eurich; Wendy I Sligl
Journal:  Can J Infect Dis Med Microbiol       Date:  2017-02-27       Impact factor: 2.471

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.